Modeling ongoing SARS-CoV2 vaccination strategies in light of emerging data on immunity and viral evolution

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3R01GM124280-04S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2018
    2023
  • Known Financial Commitments (USD)

    $173,135
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Benjamin A Lopman
  • Research Location

    United States of America
  • Lead Research Institution

    N/A
  • Research Priority Alignment

    N/A
  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease transmission dynamics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SUMMARY While SARS-CoV-2, the pathogen causing COVID-19, continues to spread, the rapid development and deployment of effective vaccines provide a means by which we can reduce its future impact. Initial vaccines have shown to be highly effective, however, the current emergence of new SARS-CoV-2 variants, together with indications that of waning immunity, means that continued repeat vaccinations are likely to be required. Here, we will build upon resources we have already developed from our ongoing project aimed at modeling potential norovirus vaccines and our previous work aimed at modeling the impact of vaccination for SARS-CoV-2 Our team has made contributions and investigated the relative population impacts of SARS-CoV-2 vaccines with different mechanisms of action; characterized patterns of virus evolution that have the potential to impact vaccine efficacy and escape; and, examined initial strategies for vaccine deployment with the aim of relaxing social distancing guidelines. We will leverage these data and modeling tools and build on this work to assess more fully the patterns of immune waning and virus evolution. We will then use these data and results and combine them with our existing SARS-CoV-2 vaccine simulation model to inform the building and the calibration of an extended model. This extended model will account for waning immunity to SARS-CoV-2 and its viral evolution. Our model will inform rapidly emerging scientific questions around continued SARS-CoV-2 vaccination and re-vaccination strategies, including both boosting and vaccine reformulation.